Elective genetic and genomic testing

Advancing Eco Agriculture (AEA) Welcomes Chief Science Officer to Advance Science Supporting Regenerative Agriculture

Retrieved on: 
Thursday, September 21, 2023
Research, Environment, Environmental Health, Sustainability, Green Technology, Other Natural Resources, Agriculture, Natural Resources, Science, Other Science, Heart, Duke University, DNA, United Space Alliance, Syngenta, Doctor of Philosophy, AEA, CSO, Genomics, Farmer, Perception, Mechanical engineering, GMO, Hope, Guild of Air Traffic Control Officers, Multimedia, Soil, Purdue University, Comparative genomics, Control, Navigation, Elective genetic and genomic testing, Chemical engineering, Conference, Johnson Space Center, Genetics

Advancing Eco Agriculture (AEA), a farm consultancy and nutritional products company that works with farmers to develop large-scale regenerative farming systems, has hired a new Chief Science Officer (CSO), Dr. Laura Kavanaugh.

Key Points: 
  • Advancing Eco Agriculture (AEA), a farm consultancy and nutritional products company that works with farmers to develop large-scale regenerative farming systems, has hired a new Chief Science Officer (CSO), Dr. Laura Kavanaugh.
  • View the full release here: https://www.businesswire.com/news/home/20230921746068/en/
    Advancing Eco Agriculture's new Chief Science Officer, Dr. Laura Kavanaugh.
  • “It's a personal goal of mine to further develop the science behind regenerative farming, shifting the perception of regenerative farming from anecdotal to highly scientific.
  • I look forward to the incredible value I know she'll add to our team, business and entire field of regenerative agriculture."

Labroots Hosts its 11th Annual Genetics Week Online Event, on May 16-18, 2023

Retrieved on: 
Thursday, May 11, 2023
Networking hardware, Senior, Molina Healthcare, Liquid biopsy, Utah Tech University, Molecular diagnostics, Doctor of Philosophy, Science, STI, Gastroenteritis, Patient, Risk, Trend News Agency, Policy, Environment, Virus, News, SCS, Informatics, Impact, Culture, Mutation, PMC, Research, Lung cancer, Bacteria, CDX, Conference, CEU, Infection, Cancer, SOC, Senior counsel, Continuing education, Standard of care, Science policy, Parasitism, Labroots, MPH, NSGC, Scale, Genetic variation, Q&A, All, Personalized medicine, Harvard Medical School, Implementation, Physician, Health, Elective genetic and genomic testing, Nursing, Vaccine, Medical imaging, Management, Genomics, Genetics, MD, Pharmacy, Medicine

YORBA LINDA, Calif., May 11, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, offering premier interactive virtual events and webinars, today announced its 11th annual Genetics Week virtual event scheduled on May 16-18, 2023. This premier scientific conference focused on advancing the frontiers of science through cutting-edge research and presented by a diverse range of leading experts from academia and institutions promises to showcase the latest developments in the fields of Genetics and Genomics, Precision Medicine and Molecular Diagnostics.

Key Points: 
  • Thousands of conference attendees will be intrigued to learn more about health outcomes, novel therapies and advancements in health systems and personalized medicine today.
  • Day three concludes the Genetics Week event bringing even more thought-provoking discussions relevant to the discipline of molecular diagnostics.
  • Produced on Labroots' comprehensive platform, while connecting across all desktop and mobile devices, the interactive environment provides an immersive educational experience.
  • Use the hashtag #LRgenetics to follow the conversation and connect with other members of the global Genetics & Genomics community!

Illumina and Deerfield Management partner to accelerate drug development

Retrieved on: 
Thursday, May 5, 2022
Corporate development, U.S. Securities and Exchange Commission, Form 10-K, Agriculture, YouTube, Instagram, Twitter, NASDAQ, Gaps, Genome, Probability, Time, Reproductive health, Drug discovery, Patient, Security (finance), Partnership, Review, Company, Illumina, Inc., Organization, DNA, Health, Efficiency, LinkedIn, Data science, Elective genetic and genomic testing, Technology, Research, SAN, Partner (business rank), Intelligence, Pharmaceutical industry, Antibiotics, Facebook, Genetics, Genomics, Illumina

SAN DIEGO, May 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs. The partnership aims to leverage genomic tools and genetic knowledge to select programs with a higher probability of success in order to lower research and development costs and accelerate the approval of cutting-edge therapies.

Key Points: 
  • "Currently, drug discovery is difficult, expensive, and slow, with 90% of therapies failing in development due to gaps in the biological understanding of the complex nature of many diseases," said Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina.
  • The partnership combines Deerfield's expertise in closing the translational drug development gap andguiding drugs through preclinical development with Illumina's industry-leading genomic data generation and AI-based genome interpretation capabilities.
  • "Illumina is an innovative global leader in genomics," said James Flynn, Managing Partner, Deerfield Management.
  • Deerfield will provide its deep expertise in translational scienceto delivergenetically validated drug candidates through the discovery research phase.

Prenatal Testing & Newborn Screening Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
General Health, Women, Consumer, Health, Genetics, Medicine, Clinical medicine, Branches of biology, Medical tests, Midwifery, Prenatal testing, Newborn screening, Down syndrome, Screening, Predictive medicine, Elective genetic and genomic testing

The "Prenatal Testing & Newborn Screening Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prenatal Testing & Newborn Screening Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The prenatal testing and newborn screening tests market consists of sales of prenatal testing and newborn screening tests services and related goods by entities (organizations, sole traders and partnerships) that provide prenatal testing and newborn screening tests, which help to determine various genetic and chromosomal diseases, to provide timely medical or surgical treatment of a condition before or after birth.
  • The use of machine learning and artificial intelligence is gradually gaining popularity in the prenatal testing and newborn screening market.
  • The prenatal testing and newborn screening market covered in this report is segmented by diagnostic type into non-invasive; invasive.

US & EU Direct-to-consumer Genetic Testing Market Trends & Growth Opportunities 2021: Genomic Players will have to Transition to Disease-specific Tests, Advanced Kits, Technology & Services - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Retail, Online Retail, Genetics, Health, Medicine, Branches of biology, Clinical medicine, Medical genetics, Medical tests, Alternatives to animal testing, Genetic testing, Medical diagnosis, Prenatal testing, Elective genetic and genomic testing

The "US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The genomic market is poised to grow at a much faster pace with real-time drug discovery, cutting-edge diagnosis, and technologically advanced treatment.
  • Genomic testing has proven to be a revolutionary tool in medicine, with applications including infectious disease diagnosis, cancer treatment selection, and non-invasive prenatal testing.
  • DTC-GT can be called directly by the consumer at home without any physician recommendation or through healthcare professionals, used for genealogy purposes.

Worldwide Rare Disease Genetic Testing Industry to 2026 - Development in Genetic Testing Technologies is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Branches of biology, Articles, Biology, Genomics, Evidence-based medicine, Precision medicine, Systems biology, Disease, Elective genetic and genomic testing, Genetic Alliance UK

In December 2020, a report published in European Centre for Disease Prevention and Control assessed the risk of new virus variants in Europe.

Key Points: 
  • In December 2020, a report published in European Centre for Disease Prevention and Control assessed the risk of new virus variants in Europe.
  • According to the survey, the pandemic negatively affected rare disease patients and caregivers due to lack of access to healthcare, diet, and treatment.
  • North America is expected to dominate the Rare Disease Genetic Testing market over the forecast period.
  • In June 2018, Genome Canada announced a national initiative of sequencing 30,000 rare disease patient samples and their relatives for precision medicine implementation.

Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions

Retrieved on: 
Thursday, April 1, 2021
Branches of biology, Health sciences, Medicine, Medical genetics, Alternatives to animal testing, Genetic testing, Clinical trial, Neurology, Elective genetic and genomic testing, Genetic counseling

The new program will make genetic testing available at no charge to individuals at risk for or suspected of having these difficult-to-diagnose conditions.

Key Points: 
  • The new program will make genetic testing available at no charge to individuals at risk for or suspected of having these difficult-to-diagnose conditions.
  • Sponsored testing programs have been shown to increase access to genetic testing, which can help confirm a diagnosis, inform treatment and enable participation in clinical trials for patients.
  • "Early access to genetic testing has been shown to significantly speed time to diagnosis in neurological conditions.
  • Cost of the testing will be underwritten by program sponsors and no patient-identifiable information will be shared with program sponsors.

My Gene Counsel Partners with O'Neal Comprehensive Cancer Center at UAB to Boost Genetic Testing and Improve Precision Cancer Care

Retrieved on: 
Tuesday, March 30, 2021
Branches of biology, Medical genetics, Medicine, Clinical medicine, Medical tests, Genetic counseling, Genetic testing, Breast cancer, Elective genetic and genomic testing

"This partnership addresses these pain points and is a game-changer for UAB, UAB patients undergoing genetic testing, and the physicians who care for them."

Key Points: 
  • "This partnership addresses these pain points and is a game-changer for UAB, UAB patients undergoing genetic testing, and the physicians who care for them."
  • My Gene Counsel's digital genetic counseling solution will soon launch within UAB's Breast Health Center to enable responsible and efficient oncologist-initiated genetic testing for breast cancer patients.
  • "My Gene Counsel's digital genetic counseling tools will enable us to coordinate genetic testing at point-of-care, allowing for more efficient genetic testing while patients are in clinic and more timely cancer treatment.
  • UAB's previous workflow required all patients undergoing genetic testing to interact with a genetic counselor before and after testing.

New Advancements in Genetic Analysis For Rare Disease Delivering Accuracy & Affordability

Retrieved on: 
Friday, March 19, 2021
Branches of biology, Medical genetics, Biology, Rare diseases, Genomics, Alternatives to animal testing, Genetic testing, Elective genetic and genomic testing

Genetic analysis is the process of screening a person for the possibility of a genetic syndrome or rare disease.

Key Points: 
  • Genetic analysis is the process of screening a person for the possibility of a genetic syndrome or rare disease.
  • In recent years there have been two main advancements that have improved the field of genetic analysis for patients who need it:
    The application of AI technology, including facial screening to genetic analysis solutions, means the analysis is faster and more accurate than ever before.
  • With other features, the need for genetic analysis might be prompted by the possibility that the features suggest a specific rare disease.
  • If we take the FDNA Telehealth platform as an example, genetic analysis will follow these simple steps:
    In recent years, genetic analysis for rare disease has come on in leaps and bounds regarding its accessibility to patients.

Global $1.8 Billion Rare Disease Genetic Testing Market to 2027: Focused Approach of Key Market Players on Cost-Effective Treatments are Driving Growth

Retrieved on: 
Tuesday, March 2, 2021
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Medical genetics, Medical tests, DNA, Genetic testing, DNA sequencing, Polymerase chain reaction, Elective genetic and genomic testing

The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player's in cost-effective treatments are the key factors responsible for market growth.

Key Points: 
  • The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player's in cost-effective treatments are the key factors responsible for market growth.
  • The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region.
  • Based on technology, the rare disease genetic testing industry is further bifurcated into next-generation sequencing, array technology, PCR-based testing, FISH, sanger sequencing, and karyotyping.
  • Based on specialty, the rare disease genetic testing industry is further bifurcated into molecular, chromosomal, and biochemical genomic tests.